[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100489378":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":311,"collaborators":24,"id":313,"slug":314,"hasResults":315,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":24,"eligibilityCriteria":319,"healthyVolunteers":315,"sex":320,"minAge":321,"maxAge":24,"enrollmentInfo":322,"targetDuration":24,"studyType":325,"phases":326,"briefSummary":328,"conditions":329,"keywords":24,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":341},{"fullName":5,"class":6},"Janssen Research & Development, LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Dose Escalation","EXPERIMENTAL","Participants will receive JNJ-79635322. The dose will be escalated sequentially until the recommended phase 2 dose (RP2D) regimen(s) have been identified.",[13],"Drug: JNJ-79635322",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 2: Dose Expansion","Participants will receive JNJ-79635322 at the RP2D regimen(s) determined in Part 1.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","JNJ-79635322","JNJ-79635322 will be administered as SC injection.",[9,15],null,[26],{"name":27,"affiliation":5,"role":28},"Janssen Research & Development, LLC Clinical Trial","STUDY_DIRECTOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"Study Contact","CONTACT","844-434-4210","Participate-In-This-Study1@its.jnj.com",[36,50,59,68,78,87,93,103,113,123,134,143,152,163,172,182,191,202,206,215,226,235,244,255,264,273,282,291,302],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":24},"City of Hope","RECRUITING","Duarte","California","91010","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-117.97729,34.13945,{"lat":48,"lon":47},{"facility":51,"status":38,"city":52,"state":40,"zip":53,"country":42,"countryCode":43,"cosmosGeoPoint":54,"geoPoint":58,"contacts":24},"City of Hope Orange County Lennar Foundation Cancer Center","Irvine","92618",{"type":45,"coordinates":55},[56,57],-117.82311,33.66946,{"lat":57,"lon":56},{"facility":60,"status":38,"city":61,"state":40,"zip":62,"country":42,"countryCode":43,"cosmosGeoPoint":63,"geoPoint":67,"contacts":24},"University of California San Francisco","San Francisco","94143",{"type":45,"coordinates":64},[65,66],-122.41942,37.77493,{"lat":66,"lon":65},{"facility":69,"status":38,"city":70,"state":71,"zip":72,"country":42,"countryCode":43,"cosmosGeoPoint":73,"geoPoint":77,"contacts":24},"Colorado Blood Cancer Institute","Denver","Colorado","80218",{"type":45,"coordinates":74},[75,76],-104.9847,39.73915,{"lat":76,"lon":75},{"facility":79,"status":38,"city":80,"state":80,"zip":81,"country":42,"countryCode":43,"cosmosGeoPoint":82,"geoPoint":86,"contacts":24},"Icahn School of Medicine at Mt. Sinai","New York","10029",{"type":45,"coordinates":83},[84,85],-74.00597,40.71427,{"lat":85,"lon":84},{"facility":88,"status":38,"city":80,"state":80,"zip":89,"country":42,"countryCode":43,"cosmosGeoPoint":90,"geoPoint":92,"contacts":24},"Memorial Sloan Kettering Cancer Center","10065",{"type":45,"coordinates":91},[84,85],{"lat":85,"lon":84},{"facility":94,"status":38,"city":95,"state":96,"zip":97,"country":42,"countryCode":43,"cosmosGeoPoint":98,"geoPoint":102,"contacts":24},"Levine Cancer Institute","Charlotte","North Carolina","28001",{"type":45,"coordinates":99},[100,101],-80.84313,35.22709,{"lat":101,"lon":100},{"facility":104,"status":38,"city":105,"state":106,"zip":107,"country":42,"countryCode":43,"cosmosGeoPoint":108,"geoPoint":112,"contacts":24},"University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine","Philadelphia","Pennsylvania","19104",{"type":45,"coordinates":109},[110,111],-75.16362,39.95238,{"lat":111,"lon":110},{"facility":114,"status":38,"city":115,"state":116,"zip":117,"country":42,"countryCode":43,"cosmosGeoPoint":118,"geoPoint":122,"contacts":24},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":45,"coordinates":119},[120,121],-95.36327,29.76328,{"lat":121,"lon":120},{"facility":124,"status":38,"city":125,"state":24,"zip":126,"country":127,"countryCode":128,"cosmosGeoPoint":129,"geoPoint":133,"contacts":24},"UZ Antwerpen","Edegem","2650","Belgium","BE",{"type":45,"coordinates":130},[131,132],4.44504,51.15662,{"lat":132,"lon":131},{"facility":135,"status":38,"city":136,"state":24,"zip":137,"country":127,"countryCode":128,"cosmosGeoPoint":138,"geoPoint":142,"contacts":24},"UZ Gent","Ghent","9000",{"type":45,"coordinates":139},[140,141],3.71667,51.05,{"lat":141,"lon":140},{"facility":144,"status":38,"city":145,"state":24,"zip":146,"country":127,"countryCode":128,"cosmosGeoPoint":147,"geoPoint":151,"contacts":24},"CHU de Liege","Liège","4000",{"type":45,"coordinates":148},[149,150],5.56749,50.63373,{"lat":150,"lon":149},{"facility":153,"status":38,"city":154,"state":24,"zip":155,"country":156,"countryCode":157,"cosmosGeoPoint":158,"geoPoint":162,"contacts":24},"CHU Nantes","Nantes","44093","France","FR",{"type":45,"coordinates":159},[160,161],-1.55336,47.21725,{"lat":161,"lon":160},{"facility":164,"status":38,"city":165,"state":24,"zip":166,"country":156,"countryCode":157,"cosmosGeoPoint":167,"geoPoint":171,"contacts":24},"CHU Lyon Sud","Pierre-Bénite","69495",{"type":45,"coordinates":168},[169,170],4.82424,45.70359,{"lat":170,"lon":169},{"facility":173,"status":174,"city":175,"state":24,"zip":176,"country":156,"countryCode":157,"cosmosGeoPoint":177,"geoPoint":181,"contacts":24},"Chu Rennes Hopital Pontchaillou","COMPLETED","Rennes","35000",{"type":45,"coordinates":178},[179,180],-1.67431,48.11109,{"lat":180,"lon":179},{"facility":183,"status":38,"city":184,"state":24,"zip":185,"country":156,"countryCode":157,"cosmosGeoPoint":186,"geoPoint":190,"contacts":24},"Institut Claudius Regaud","Toulouse","31100",{"type":45,"coordinates":187},[188,189],1.44367,43.60426,{"lat":189,"lon":188},{"facility":192,"status":38,"city":193,"state":24,"zip":194,"country":195,"countryCode":196,"cosmosGeoPoint":197,"geoPoint":201,"contacts":24},"Japanese Red Cross Medical Center","Shibuya City","150-8935","Japan","JP",{"type":45,"coordinates":198},[199,200],139.70665,35.6589,{"lat":200,"lon":199},{"facility":203,"status":38,"city":204,"state":24,"zip":205,"country":195,"countryCode":196,"cosmosGeoPoint":24,"geoPoint":24,"contacts":24},"Osaka University Hospital","Suita-shi","565-0871",{"facility":207,"status":174,"city":208,"state":24,"zip":209,"country":195,"countryCode":196,"cosmosGeoPoint":210,"geoPoint":214,"contacts":24},"The Cancer Institute Hospital of JFCR","Tokyo","135-8550",{"type":45,"coordinates":211},[212,213],139.69171,35.6895,{"lat":213,"lon":212},{"facility":216,"status":38,"city":217,"state":24,"zip":218,"country":219,"countryCode":220,"cosmosGeoPoint":221,"geoPoint":225,"contacts":24},"VUMC Amsterdam","Amsterdam","1081 HV","Netherlands","NL",{"type":45,"coordinates":222},[223,224],4.88969,52.37403,{"lat":224,"lon":223},{"facility":227,"status":38,"city":228,"state":24,"zip":229,"country":219,"countryCode":220,"cosmosGeoPoint":230,"geoPoint":234,"contacts":24},"Universitair Medisch Centrum Groningen","Groningen","9713 GZ",{"type":45,"coordinates":231},[232,233],6.56667,53.21917,{"lat":233,"lon":232},{"facility":236,"status":38,"city":237,"state":24,"zip":238,"country":219,"countryCode":220,"cosmosGeoPoint":239,"geoPoint":243,"contacts":24},"UMC Utrecht","Utrecht","3584 CX",{"type":45,"coordinates":240},[241,242],5.12222,52.09083,{"lat":242,"lon":241},{"facility":245,"status":38,"city":246,"state":24,"zip":247,"country":248,"countryCode":249,"cosmosGeoPoint":250,"geoPoint":254,"contacts":24},"Hosp. Univ. Germans Trias I Pujol","Badalona","08916","Spain","ES",{"type":45,"coordinates":251},[252,253],2.24741,41.45004,{"lat":253,"lon":252},{"facility":256,"status":38,"city":257,"state":24,"zip":258,"country":248,"countryCode":249,"cosmosGeoPoint":259,"geoPoint":263,"contacts":24},"Hosp Clinic de Barcelona","Barcelona","08036",{"type":45,"coordinates":260},[261,262],2.15899,41.38879,{"lat":262,"lon":261},{"facility":265,"status":38,"city":266,"state":24,"zip":267,"country":248,"countryCode":249,"cosmosGeoPoint":268,"geoPoint":272,"contacts":24},"Hosp Univ Fund Jimenez Diaz","Madrid","28040",{"type":45,"coordinates":269},[270,271],-3.70256,40.4165,{"lat":271,"lon":270},{"facility":274,"status":38,"city":275,"state":24,"zip":276,"country":248,"countryCode":249,"cosmosGeoPoint":277,"geoPoint":281,"contacts":24},"Clinica Univ. de Navarra","Pamplona","31008",{"type":45,"coordinates":278},[279,280],-1.64323,42.81687,{"lat":280,"lon":279},{"facility":283,"status":38,"city":284,"state":24,"zip":285,"country":248,"countryCode":249,"cosmosGeoPoint":286,"geoPoint":290,"contacts":24},"Hosp Clinico Univ de Salamanca","Salamanca","37007",{"type":45,"coordinates":287},[288,289],-5.66388,40.96882,{"lat":289,"lon":288},{"facility":292,"status":38,"city":293,"state":24,"zip":294,"country":295,"countryCode":296,"cosmosGeoPoint":297,"geoPoint":301,"contacts":24},"University College Hospital","London","W1T 7HA","United Kingdom","UK",{"type":45,"coordinates":298},[299,300],-0.12574,51.50853,{"lat":300,"lon":299},{"facility":303,"status":38,"city":304,"state":24,"zip":305,"country":295,"countryCode":296,"cosmosGeoPoint":306,"geoPoint":310,"contacts":24},"Royal Marsden Hospital","Sutton","SM2 5PT",{"type":45,"coordinates":307},[308,309],-0.2,51.35,{"lat":309,"lon":308},{"type":312,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100489378","phase-1-a-study-of-jnj-79635322-in-participants-with-relapsed-or-refractory-multiple-myeloma-or-previously-treated-amyloid-light-chain-al-amyloidosis-100489378",false,"NCT05652335","A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis","Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis","Inclusion Criteria:\n\nFor participants with relapsed or refractory multiple myeloma:\n\n* Have a documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria\n* Part 1: Have relapsed or refractory disease, have been treated with a proteasome inhibitor, immunomodulatory drug (IMiD) agent, and an anti-CD38-based therapy for the treatment of multiple myeloma (MM),and should have been treated with at least 3 prior lines of therapy, or are refractory to proteosome inhibitor, IMiD agent, and an anti-CD38-based therapy regardless of prior lines of therapy, Part 2: Have relapsed or refractory disease, have been treated with a PI, IMiD and an anti-CD38 based therapy\n* Must have an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1\n* Have measurable disease at screening as defined by at least 1 of the following: a) Serum M-protein level greater than or equal to (\\>=) 0.5 grams per deciliter (g\u002FdL); or b) Urine M-protein level \\>=200 milligrams (mg)\u002F24 hours; or c) Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) \\>=10 milligrams per deciliter (mg\u002FdL) and abnormal serum Ig kappa lambda FLC ratio; d) For participants without measurable disease in the serum, urine, or involved FLC, presence of 1 or more focus of extramedullary disease (EMD) which meets the following criteria: extramedullary plasmacytoma not contiguous with a bone lesion, at least 1 lesion \\>=2 centimeter \\[cm\\] (at its greatest dimension) diameter on whole body Positron Emission Tomography and Computed Tomography (PET-CT) Scans (or whole body magnetic resonance imaging \\[MRI\\] approved by sponsor), and not previously radiated (Part 2C participants are not required to have measurable disease)\n\nFor participants with previously treated AL amyloidosis:\n\n* Initial histopathological diagnosis of amyloidosis\n* Participant who is not a candidate for available AL amyloidosis therapy with established clinical benefit and should have received at least 3 cycles of 1 prior line of therapy or a total of at least 2 cycles of 2 or more prior lines of therapy for AL amyloidosis\n* Measurable disease at screening defined by at least 1 of the following: serum involved free light chain (iFLC) \\>=50 mg\u002FL or difference between involved and uninvolved free light chains (dFLC) \\>=50 mg\u002FL, or serum m-protein \\>= 0.5 g\u002FdL\n* One or more organs impacted by systemic AL amyloidosis\n* Left ventricular ejection fraction (LVEF) \\>=45%\n\nExclusion Criteria:\n\nFor participants with relapsed or refractory multiple myeloma:\n\n* Central Nervous System (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma. If either is suspected, brain magnetic resonance imaging (MRI) and lumbar cytology are required\n* Active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or primary light chain amyloidosis\n* Received a cumulative dose of corticosteroids equivalent to greater than (\\>) 140 mg of prednisone within the 14-day period before the start of study treatment administration\n* Prior antitumor therapy as follows, in the specified time frame prior to the first dose of study treatment: (proteasome inhibitor \\[PI\\] therapy or radiotherapy within 14 days, immunomodulatory drug (IMiD) agent therapy within 7 days, gene-modified adoptive cell therapy within 90 days \\[not applicable for Part 2C participants\\], or CD3-redirecting therapy within 21 days\\[not applicable for Part 2B or 2C participants\\])\n* Prior allogeneic transplant within 6 months before the start of study treatment administration or autologous transplant within 12 weeks before the start of study treatment administration\n* Live, attenuated vaccine within 4 weeks before the first dose of study treatment\n* Non-hematologic toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (\\\u003C=) 1 (except alopecia, tissue post-RT fibrosis \\[any grade\\] or peripheral neuropathy to Grade \\\u003C=3)\n* The following medical conditions: pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation, human immunodeficiency (HIV) infection, active hepatitis B or C infection, stroke or seizure within 6 months prior to first dose of study treatment, autoimmune disease, serious active viral or bacterial infection, uncontrolled systemic fungal infection, cardiac conditions (myocardial infarction \\\u003C=6 months prior to enrollment, New York Heart Association stage III or IV congestive heart failure, et cetera)\n* Part 2C: have progressive disease or refractory disease per IMWG after CAR-T administration\n\nFor participants with previously treated AL amyloidosis:\n\n* CNS involvement or clinical signs of meningeal involvement of AL amyloidosis. If either is suspected, whole brain MRI and lumbar cytology are required\n* Any form of non-AL amyloidosis, including but not limited to transthyretin (ATTR) amyloidosis\n* Active plasma cell leukemia, Waldenstrom's macroglobulinemia, or POEMS syndrome\n* Pulmonary compromise requiring supplemental oxygen use\n* Any serious medical conditions such as: active viral, bacterial, fungal infection; active autoimmune disease; HIV infection, active hepatitis B or C infection, stroke or seizure within 6 months prior to first dose of study treatment, significant cardiovascular conditions\n* Previous or current diagnosis of symptomatic multiple myeloma\n* Macroglossia that impairs swallowing difficulty\n* Received a cumulative dose of corticosteroids equivalent to \\> 140 mg of prednisone within the 14-day period before the start of study treatment administration\n* Prior antitumor therapy within 21 days prior to the first dose of study treatment (PI therapy or radiotherapy within 14 days, IMiD agent therapy within 7 days, gene-modified adoptive cell therapy within 90 days, or CD3-redirecting therapy within 21 days)\n* Prior allogeneic transplant within 6 months before the start of study treatment administration or autologous transplant within 12 weeks before the start of study treatment administration\n* Live, attenuated vaccine within 4 weeks before the first dose of study treatment\n* Non-hematologic toxicity from prior anticancer therapy that has not resolved to baseline levels or to \\\u003C=1 (except alopecia, tissue post-RT fibrosis \\[any grade\\] or peripheral neuropathy to Grade \\\u003C=3)","ALL","18 Years",{"count":323,"type":324},180,"ESTIMATED","INTERVENTIONAL",[327],"PHASE1","The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\\[s\\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).",[330,331],"Relapsed or Refractory Multiple Myeloma","Previously Treated Amyloid Light-chain (AL) Amyloidosis","2026-06-04",{"date":334,"type":335},"2026-06-05","ACTUAL",{"date":337,"type":335},"2022-11-22",{"date":339,"type":324},"2028-08-28",{"name":5,"class":6},29]